Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
SOHM Inc (SHMN) delivers innovative solutions at the intersection of generic pharmaceuticals and advanced gene editing. This news hub provides investors and industry observers with timely updates on the company’s financial developments, research milestones, and strategic initiatives.
Access authoritative reports on earnings announcements, regulatory filings, and technology advancements like the ABBIE genome editing system. Stay informed about partnerships with leading institutions and progress in CAR-T cell therapy applications.
Our curated collection features press releases detailing manufacturing expansions, cosmeceutical product launches, and biotech collaborations. Discover updates on patent approvals, clinical trial developments, and market expansion strategies.
Bookmark this page for streamlined access to verified information about SHMN’s dual focus areas. Check regularly for new insights into how SOHM Inc navigates the evolving biopharmaceutical landscape through its integrated business model.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced a new collaboration with Stanford University. This partnership aims to advance cell engineering and gene editing through SOHM's ABBIE Technology. The collaboration will involve joint research projects, knowledge-sharing initiatives, and technology development programs.
Dr. David Aguilar, COO of SOHM, expressed excitement about the partnership, stating that it will amplify their impact and foster innovation. Specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. This strategic alliance combines SOHM's innovative prowess with Stanford's expertise to tackle challenges in gene editing development.
SOHM has announced promising preliminary data from their ABBIE genome editing technology, showcasing successful engineering of a CAR-T cell from a healthy donor that killed lung cancer cells in experimental models. This breakthrough, presented at the 2024 AACR conference, highlights ABBIE's novel approach, utilizing mRNA or purified protein delivery instead of traditional virus-based systems. This could offer a more efficient and less toxic method for developing cancer immunotherapies. The market for such therapies is projected to grow significantly, with CAR T-cell therapy costs ranging from $373,000 to $475,000 per patient.
SOHM targets the release of its revolutionary ABBIE genome editing kits by Q3 2024. ABBIE, a retroviral integrase with a linked dCas9 DNA binding domain, promises precise and targeted integration of donor DNA into cell genomes. This breakthrough technology could significantly advance genetic engineering, offering new treatment possibilities for genetic diseases and novel therapies. The company expects high demand and significant revenue from the first generation of ABBIE kits, projecting thousands of units sold and millions in revenue. Additional related products are also under development.
FAQ
What is the current stock price of Sohm (SHMN)?
What is the market cap of Sohm (SHMN)?
